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Abstract
Pooled F(ab')2 fragments of three MAbs against distinct epi-
topes of carcinoembryonic antigen (CEA) were used for ra-
dioimmunotherapy of nude mice bearing a subcutaneous
human colon carcinoma xenograft. 9-10 d after transplantation
when tumor nodules were in exponential growth, 36 mice were
treated by intravenous injection of different amounts of '31I-la-
beled MAb F(ab')2. All 14 mice injected with a single dose of
2,200 (n = 10) or 2,800 gCi (n = 4) showed complete tumor
remission. 8 of the 10 mice treated with 2,200 gCi survived in
good health for 1 yr when they were killed and shown to be
tumor free. Four of nine other mice treated with four fraction-
ated doses of 400,gCi showed no tumor relapse for more than 9
mo. In contrast, all 15 mice injected with 1,600-3,000 gCi
'311-control IgG F(ab')2 showed tumor growth retardation of
only 1-4 wk, and 15 of 16 mice injected with unlabeled anti-
CEA MAb F(ab')2 showed unmodified tumor progression as
compared with untreated mice. From tissue radioactivity dis-
tributions it was calculated that by an injection of 2,200 1MCi
'31I-MAb F(ab')2 a mean dose of 8,335 rad was selectively
delivered to the tumor, while the tissue-absorbed radiation
doses for the normal organs were: peripheral blood, 2,093;
stomach, 1,668; kidney, 1,289; lung, 1,185; liver, 617; spleen,
501; small intestine, 427; large intestine, 367; bone, 337; and
muscle, 198. These treatments were well tolerated since out of
19 mice with complete tumor remission only 4 required bone
marrow transplantation and 17 were in good health for 6-12
mo of observation. The results demonstrate the selective de-
struction of established human colon carcinoma transplants by
intravenous injection of either single or fractionated doses of
111-MAb F(ab')2.
Introduction
After the discovery of the hybridoma technology (1), which
allows the production of MAbs directed against new tumor-
associated antigens (2-5) and selective antigenic determinants
of known tumor markers such as carcinoembryonic antigen
(CEA)' (6, 7), there has been renewed interest in antibody-me-
Address reprint requests to Dr. Franz Buchegger, Institute of Biochem-
istry, CH-1066 Epalinges, Switzerland.
Received for publication 13 April 1988 and in revised form 21
November 1988.
1. Abbreviations used in this paper: BMC, bone marrow cells; CEA,
carcinoembryonic antigen; WBC, white blood cells.
diated cancer therapy. Several clinical trials of cancer treat-
ment with unlabeled antibodies involving patients with leuke-
mia, lymphoma (8, 9), melanoma (10-13), and colon carci-
noma (14) have recently been reported. Antibodies coupled to
toxins were used in a therapeutic trial of melanoma patients
(15). Polyclonal and monoclonal antibodies carrying a radio-
isotope of medium or high beta energy like '3'I or 9Y have
been used in some clinical tumor therapy trials (16-22). The
theoretical advantage of such isotopes consists in their emis-
sion of electron particles that can penetrate and damage sev-
eral cell layers around the targeted tumor cells. Thus, within a
solid tumor nodule cells with low antigen expression can be
lethally hit by electrons emitted from radiolabeled antibodies
concentrated on adjacent tumor cells expressing more antigen.
We have selected for immunoscintigraphy of colorectal
carcinomas several anti-CEA MAbs (23, 24) and have recently
reported their use in a murine radioimmunotherapy model
(25) as well as in a therapeutic approach in colorectal carci-
noma patients (26). The treatment was well tolerated by the
patients, but the doses of radioactivity delivered to the tumors
were too low to produce tumor regression.
In nude mice grafted with colon carcinoma we have ob-
tained specific but limited tumor regressions by using a mix-
ture of intact MAbs and their F(ab')2 fragments labeled with
I'lI (25). We describe here, in the same model, definitively
more successful therapeutic results obtained by the exclusive
use of F(ab')2 fragments of the same anti-CEA MAbs labeled
with higher doses of 1311. Under stringent experimental condi-
tions, including the initiation of therapy only 9-10 d after
tumor transplantation and an intravenous mode of antibody
administration, we have obtained complete remission of
human colon carcinoma xenografts in a significant number of
mice without altering their long-term survival. These results
compare favorably with previous reports from the literature
(27-39). A precise dosimetry, based on a time course study of
the tissue distribution of "'1I in dissected animals, gives infor-
mation that might be helpful for designing antibody-guided
radioimmunotherapy trials in patients with disseminated
colon carcinomas.
Methods
MAbs. F(ab)2 fragments from three MAbs (MAb 35, CE-25-B7 [B7],
and B17) against three independent epitopes of CEA were selected
according to criteria required for therapeutic injection of patients (26,
40), including high percentage of binding to purified CEA and no
reaction with (a) the cross-reacting antigens NCA-55 and NCA-95 (41,
42), (b) biliary glycoprotein (43), and (c) fresh human granulocytes.
The '3II-labeled F(ab')2 fragments from the three MAb were shown to
localize equally well into human colon carcinoma xenografts yielding
high tumor to whole body ratios ranging from 35 to 50 (25).
Preparation ofF(ab)2fragments. Antibodies or IgG from ascites of
the three hybridomas 35, B7, and Bl 7, and ofthe IgG,-secreting mouse
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myeloma P3 X 63 (1) were precipitated with ammonium sulfate, the
redissolved sediment was digested with pepsin, and F(ab')2 fragments
were purified as described earlier (25, 44). F(ab')2 fractions were shown
to be 95-98% pure by SDS-PAGE.
Labeling ofF(ab)2 with 131L Batches of 1 mg of F(ab')2 fragments
from single or pooled anti-CEA MAbs were labeled by the chloramine
T method with 10 mCi of 30I yielding a specific activity of 8-9 MCi/Mg.
Immunoreactivity of radiolabeled F(ab')2 was determined as described
earlier (25).
Nude mouse tumor model and therapeutic modalities. The human
colon carcinoma T380, generously provided by S. Halpern, San Diego
(45), was serially transplanted subcutaneously (46) into 7-9-wk-old
male "Swiss" homozygous nu/nu mice (Iffa Credo, I'Arbresle, France).
Tumor T380 contains almost no necrotic areas, is moderately differ-
entiated, and contains numerous pseudolumina that are rich in
CEA (45).
The mice were held in aseptic conditions using filter paper-topped
cages and nourished with standard, vitamin-supplemented, and irra-
diated food. In addition, drinking water (maintained at pH 6) was
supplemented with a polyvitamin (Protovit iv, 0.1 ml/300 ml water;
Roche, Basel, Switzerland), and amino acid preparations (Polilevo iv,
0.05 ml/300 ml water; Piniol AG, Horw, Switzerland). Lugol iodine
(5%) solution was added into drinking water (0.2 ml/300 ml) 3 d before
and up to 6 wk after injection of 131I-F(ab')2.
8-10 d after subcutaneous injection of 50 mm3 of minced tumor
T380 into the right flanks of the animals, I 90% of the transplants
entered into exponential growth.
Therapy was started at day 9 or 10 after tumor transplantation.
Nude mice were selected for evidence of tumor growth and randomly
distributed into the different therapy and control groups. For each of
the three series of experiments (described in Figs. 1-3), '31I-labeled
anti-CEA MAb F(ab')2, 131I-labeled control IgG F(ab')2, and unlabeled
anti-CEA MAb F(ab')2 were intravenously injected at the same day,
while another control group remained untreated.
Follow-up oftreated and control mice. Three different diameters of
the tumors were measured two times a week for 50 d and then once a
week. Tumor volume was calculated by the formula vol = r, X r2 X r3
X 4/3 wr (r = radius). The precision of these measurements was found to
be ± 10-15% when performed by different observers, by comparison of
results obtained by external tumor measurements, and by direct
weighing of 20 dissected tumors.
Whole body counting was performed just after injection of '3'I-
F(ab')2 and every 1-2 d thereafter using an assayer (RADX Corp.,
Houston, TX). On the day ofinjection and every 2-3 d thereafter, mice
were weighed until they recovered from the initial weight loss. At 4, 7,
14, 21, 28, and 35 d after injection of '3'I-MAb or control F(ab')2,
blood was taken from the tail vein and peripheral white blood cells
(WBC) were counted.
Statistical analysis. Concerning duration of regression or cure
rates, statistical analysis was performed with the t test (quantitative
analysis) or with the x2 test (qualitative analysis), respectively.
Bone marrow transplantation. Nude mice with peripheral WBC
falling below 2,000 cells/mm3 were transplanted as prevention against
infections with bone marrow cells (BMC) from a healthy nude mouse
of the same Swiss genetic background. Donor mice were killed and
BMC were washed out from the long bones (femur, tibia, and hu-
merus) with a small volume of serum-free culture medium. 10-12
X 106 BMC were recovered from each donor mouse and 3-4 X 106
BMC were injected intravenously per recipient mouse (47).
Dosimetry for tumor and normal organs. 18 mice were injected
with 10 MCi of '311-anti-CEA MAb F(ab')2 (labeled as for treatment)
together with 275 ug of unlabeled anti-CEA MAb fragments. At dif-
ferent times after injection, groups of three mice were killed and dis-
sected, and the tissue distribution of radioactivity was measured in a
gamma counter.
In more recent experiments eight tumor-bearing mice were in-
jected with 400 MCi of '3'i on 50 ,g anti-CEA MAb F(ab')2. The mice
were dissected at 4, 8, 24, and 48 h after injection, and tissue distribu-
tion of radioactivity was measured.
From the directly measured tissue radioactivity, an integral dose of
MCi X hours was calculated per gram oftumor and the normal organs
(for the doses received after 48 h, a 24-h t1/2 decrease of radioactivity
was taken into account based on whole body "'I measurements). Tis-
sue-absorbed beta radiation was calculated by the formula Do = 2.13
X IACi/g tissue X h X En rad (where Ed = 0.19 g/gCi per h for '3'I) for
tumor, normal organs, and whole body. An additional gamma radia-
tion dose (Do) was assumed to be equally distributed to all normal
mouse organs and tumor; D, whole body dose is 10% ofthe D;, whole
body dose for a 30-g mouse (25, 48).
Results
Quality control of radiolabeled F(ab)2. F(ab')2 fragments of
each individual and of the pool of the three selected MAbs
reacting with independent epitopes on the CEA molecule were
radiolabeled with therapeutic doses of "'lI and analyzed for
their binding capacity to CEA immobilized on CNBr-activated
Sepharose (Pharmacia Fine Chemicals, Uppsala, Sweden).
The different labelings gave 58-75% binding after incubation
with a limited excess of'Sepharose-CEA, and < 2% binding
with human peripheral WBC.
Therapy with increasing doses of'3I-labeledMAb F(ab')2.
400, 800, 1,600, and 2,800 gCi '31I-anti-CEA MAb F(ab')2
were injected as a single dose at day 9 after tumor transplanta-
tion in four groups of four to five mice. Mice treated with 400
and 800 ,Ci showed tumor regression lasting for a mean'of 17
d (range 12-24 d) and 24 d (range 15-33 d), respectively (Fig. 1
B). Four out of five mice treated with 1,600 MCi showed tumor
regression lasting from 59 to 85 d (mean 74 d), significantly
different from the groups injected with 400 or 800 1uCi (2P
< 0.001). In the fifth mouse a complete tumor regression per-
sisted 6 mo after therapy. All four mice treated with 2,800 ,Ci
showed complete tumor regression. Three ofthe last four mice
were given bone marrow transplantations at day 7 after ther-
apy because of WBC depression. All four mice treated with
2,800 /Ci and one out of five mice treated with 1,600 ACi of
'I-F(ab`)2 were tumor free and in good health 6 mo after
injection, when they were killed for histologic examination.
Three control mice received an injection of 3,000 1sCi of
normal IgG F(ab')2 and showed minimal tumor regression that
lasted for a mean time of 23 d (range 20-25 d). All three
control mice required bone marrow transplantation. The
tumor regressions observed after injection of 3,000 ACi normal
IgG F(ab')2 were significantly shorter when compared with
mice injected with 1,600 or 2,800 MCi MAb F(ab')2 with 2P
< 0.001 for both comparisons.
Six mice were injected with 350 ,g of unlabeled anti-CEA
MAb F(ab')2 (an amount offragments corresponding to that of
the 2,800-!sCi injections). Five out of six mice showed expo-
nential tumor progression similar to that of the six untreated
mice, reaching a tumor size of more than 1,000 mm3 within
20-40 d, whereas one mouse showed complete tumor regres-
sion (Fig. 1 A) (P < 0.01 comparing 2,800 jiCi '31I-labeled vs.
350 ltg unlabeled MAb F(ab')2).
Therapy with repeated doses of400 AtCi 13]I-MAb F(ab'h.
Four doses of400 AGCi '3I-MAb F(ab')2 were injected into nine
mice at days 10, 12, 24, and 38 after tumor transplantation.
Tumor regression was observed'in all nine mice, as shown in
Fig. 2. In four mice, the regression is complete with no relapse
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after 9 mo of observation. These four mice were in good health
with normal body weight. The five other mice showed tumor
regression lasting for a mean of 60 d (range 55-70 d). Relaps-
ing tumors in this group were mostly tumors that were bigger
at the time of '31I-MAb F(ab')2 injection.
The injection of seven control mice with four repeated
doses of 400 AiCi "1'I-normal IgG F(ab')2 had only a minimal
effect on tumor growth which was retarded for 4-17 d (mean 9
d) as compared with untreated controls. Comparison of results
in mice treated with '1I-anti-CEA MAb F(ab')2 and with 13.I-
normal IgG F(ab')2 in terms of cure rates (four of nine vs. zero
of seven) as well as of regression duration in relapsing animals
(60±6 d vs. 8.9±5.8 d) gave significant differences (P < 0.05
and 2P < 0.001, respectively). Four injections of the corre-
sponding amount of unlabeled MAb F(ab')2 (50 Ag) had no
inhibitory effect on tumor growth in five mice.
Therapy with 2,200 uCi '31I-MAb F(ab')2 in a single dose.
A group of 10 mice was treated 10 d after tumor transplanta-
tion with a single dose of 2,200 qCi '31I-anti-CEA MAb
F(ab')2. All 10 mice showed complete tumor remission (Fig.
3). Eight of these mice were still tumor free and in good health
1 yr after therapy when they were killed. Two mice were killed
at 4 and 8 mo after therapy because of progressive ulcerative
skin disease or cachexia.
The same amount of 2,200 tCi of '"'I coupled to normal
IgG F(ab')2, injected in five control mice, resulted in short
tumor regressions lasting for only 17-24 d (mean 21 d) (P
< 0.001 when '3'1-normal IgG F(ab')2 are compared with ''I-
anti-CEA MAb F(ab')2). In a group of five mice injected with
the corresponding amount of unlabeled anti-CEA MAb
F(ab')2 (275 gg), all five mice showed unmodified tumor
growth as compared with untreated mice and reached a tumor
size of more than 1 g within 20-40 d after transplantation.
Calculation of radiation doses for tumor and normal tis-
sues. 18 mice were injected with 10 ,Ci '3'I-anti-CEA MAb
F(ab')2 mixed with 275 ,ug of unlabeled anti-CEA MAb frag-
-...I................. . .300 - 5../5...^^, 131I3 00 : .w j/{.:/5*............ ............ ....... ....rA
~Zunlabez E=4runtrea
2 range
200..........:, range
100 ..... ..
DAYS AFTER TUMOR TRANSPL
ments (corresponding to the amount of fragments in the 2,200
1iCi therapy group). At different times after injection (1, 4, 8,
12, 24, and 48 h), groups of three mice were killed and dis-
sected, and the tissue distribution of radioactivity was mea-
sured in a gamma counter. Fig. 4 shows that a plateau of
20% of injected dose per gram of tumor was obtained be-
tween 4 and 12 h after injection, with a maximum value of
20.7% at 8 h. Beyond 12 h a steady decline of tumor radioac-
tivity with t/2 of - 24 h was observed. Interestingly, the max-
imum percentage of the anti-CEA MAb F(ab')2 (20.7% = 57
,gg) localized per gram oftumor (containing - 40 Ag ofCEA)
(45) corresponds to almost a saturation of each CEA molecule
of 200 kD with three F(ab')2 fragments of 100 kD.
From the tissue distributions of I1I-MAb F(ab')2 (Fig. 4) an
integral dose of microcuries X hours per gram tumor and nor-
mal organs was calculated, and thereof the tissue-absorbed
radiation doses (25, 48). The results indicate that for an injec-
tion of 2,200 ,Ci of "3'I coupled to 275 ytg ofMAb F(ab')2 the
mean radiation doses were 8,335 rad for the tumor, 2,093 rad
for the blood, 1,668 rad for the stomach, 1,289 rad for the
kidney, 1,185 rad for the lung, 617 rad for the liver, 501 rad for
the spleen, 427 rad for small bowel, 367 rad for large bowel,
and 337 rad for the bones (Table I). The radiation dose ab-
sorbed by bone marrow was not determined, but we can as-
sume that it is similar to the 501 rad absorbed by the spleen.
Such a dose of bone marrow irradiation appears consistent
with the modest depression of peripheral WBC in 9 of 10 mice
treated with 2,200 tCi of 'I.
In this experiment a high dose of radioactivity was deliv-
ered to the tumor with a single injection of '311-MAb F(ab')2,
but the percentage of injected dose in tumor was not optimal.
After injection of lower amounts (50 jig) of the same F(ab')2
fragments a significantly higher percentage ofinjected dose per
gram tumor was reached at 8 h (mean 36.4%±1.9%, three
mice) as compared with injection of the larger amounts (275
jig) of F(ab')2 (20.7+3.2%, three mice) (2P < 0.005) (Table I,
Figure 3. Tumor size in mice
injected with a single dose of
2 200 IiCi MAb F(ab')2.
Three groups of mice were
injected 10 d after tumor
-_-_._:_: transplantation, either with a
F(a.)2 single dose of 2,200 ACi '"'I-
J F(ab )2 anti-CEA MAb F(ab')2, the
§MAb F(ab) ^ q same amount of 'I coupled)2 A @. , to control IgG F(ab')2, or the
mice . ^ corresponding amount of un-
trol
~~~~~~labeled anti-CEA MAb
rapy ...... S ;.S.S S S S....F(ab')2(275 ,g). A fourth
group of mice was untreated.
The mean tumor size for
each group is represented by
thick lines. The range in
tumor size in the control
::: groups is represented by the
dashed lines, while the range
in tumor size of '3'I-anti-
__ CEA MAb F(ab`)2-treated
animals is shown by two thin
lines. A mouse in the anti-
I ,,"'h body-treated group killed at190 100 110 260 4 mo because of ulcerative
ANTATION skin disease is indicated by t.
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column 3). Therefore, possible approaches to reach optimal
tumor to normal tissue ratios in therapy protocols would be to
use repeated injections of '311-MAb F(ab')2 (as our results ob-
tained in mice injected with 4 X 400 ,Ci indicate) or to label
MAb fragments to higher specific activities by new labeling
procedures (49).
Table I. Tissue-absorbed Radiation Doses after Injection
of'3'I-labeled Anti-CEA MAb F(all)2 Fragments
2,200 ;iCi (275 ug) F(aW)2 400 uCi (50 pg) F(ab')2
and tumor to normal and tumor to normal
Organ tissue ratios* tissue ratios*
Tumor 8,335$ 2,167§
Blood 2,093 (4.0)* 440 (4.9)*
Liver 617 (13.5) 137 (15.8)
Kidney 1,289 (6.5) 227 (9.5)
Lung 1,185 (7.0) 203 (10.7)
Stomach 1,668 (5.0) 330 (6.6)
Small intestine 427 (19.5) 86 (25.0)
Large intestine 367 (22.7) 70 (31.0)
Spleen 501 (16.6) 106 (20.4)
Bone 337 (24.7) 73 (29.7)
* The tumor to normal tissue radiation ratios are obtained by divid-
ing the tumor radiation dose by that of each normal tissue.
t Mean calculated radiation dose in rad per organ. Data obtained
from 18 tumor-bearing mice from which radioactivity tissue distribu-
tion are shown in Fig. 4.
0 Mean calculated radiation dose in rad per organ. Data obtained
from eight tumor-bearing mice injected with 400 ACi MAb F(ab')2 in
a preliminary experiment.
Figure 4. Evolution of
the biodistribution in
tumor and normal tissues
after injection of 'Ii-
MAb F(ab')2. 18 mice
were each injected with
10 MCi of '1I-anti-CEA
MAb F(ab')2 (1.2 ,g pro-
tein) mixed with 275 ,g
of unlabeled anti-CEA
MAb F(ab')2. At different
times(l, 4, 8, 12, 24, and
48 h) after injection,
three mice were killed
and the radioactivity in
the tumor and normal
organs was measured.
The bars represent the
percentages of injected
dose per gram of tumor
(T, black bars) and of dif-
ferent normal organs
(shaded bars), including
liver (Li), kidneys (K),
lung (L), spleen (S), mus-
cle (M), and blood (B).
Vertical lines represent I
SD. This tissue distribu-
tion analysis represents
the basis for the dosime-
tric calculations.
Short-term toxicity after injection of radiolabeled frag-
ments. The weight of treated and control mice was measured
at days 0, 2, 4, 7, 14, and 21 after injection. The mean weight
of the mice of all groups was - 30 g at the beginning of ther-
apy. An average weight loss of 10% ranging from 8 to 15% was
observed at day 4 after injection of 1,600 or more MCi of "3'I
coupled to either antibody or control IgG F(ab')2 fragments.
5% or insignificant weight loss was seen in mice injected with
800 MCi or less of 31I-F(ab')2, as well as in the mice injected
with unlabeled MAb. Normal weights were recovered within
2-3 wk after injection.
Peripheral WBC were repeatedly controlled at 4, 7, 14, 21,
28, and 35 d after radioactivity injection. Untreated tumor-
bearing mice had 9,000-18,000 (mean 13,200, 15 mice)
WBC/mm3. Moderately decreased WBC values ranging from
3,500 to 9,000 (mean 5,800, eight mice)/mm3 were observed
2-3 wk after injection of 400-800,uCi. After injection of 1,600
,MCi the WBC decreased to values ranging from 2,100 to
8,300/mm3 (mean 3,600, five mice) already at 7 d after injec-
tion. Higher amounts of radioactivity (2,200 and 2,800 MCi)
gave more severe WBC depression with values ranging from
1,100 to 5,700/mm3 (mean 3,200, 14 mice) 4-7 d after injec-
tion. Nevertheless, only 1 of 10 mice injected with 2,200 MACi
and 3 of 4 mice injected with 2,800 MCi '311-anti-CEA MAb
fragments required bone marrow transplantation because
WBC fell below 2,000/mm3. More severe WBC depression
with values ranging from 250 to 1,150 cells/mm3 (mean 730,
eight mice) was observed after injection of2,200 and 3,000 MCi
'311-labeled control mouse IgG F(ab')2, which, as has been
shown earlier (25), had a longer whole body tI2 than anti-CEA
MAb F(ab')2. Thus, all the five mice injected with 2,200 sCi
and the three mice injected with 3,000 MiCi of '311-normal IgG
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F(ab')2 required bone marrow transplantation. Peripheral
WBC values began to rise at 7-10 d after bone marrow trans-
plantation and in transplanted as well as untransplanted mice
WBC completely recovered at 3-5 wk after injection of radio-
labeled MAb.
Long-term toxicity after injection of radiolabeled frag-
ments. In all treatment groups the mice showed no toxic side
effects except for the bone marrow depression. 2 of the group
of 10 mice successfully treated with 2,200 gCi MAb F(ab')2
were killed at 4 and 8 mo after therapy because of progressive
ulcerative skin disease or cachexia. The organs from several
other mice killed up to 6 mo after treatment with 1,600-2,800
11Ci of 131I-MAb F(ab')2 were examined histologically. No evi-
dence of tissue necrosis or fibrosis was detected.
Morphology and CEA expression in relapsing tumors.
Tumors from six mice relapsing at 55-75 d after therapy with
1,600 uCi 131I-MAb F(ab')2 administered in a single dose (ex-
periment 1, n = 3) or in fractionated doses (experiment 2, n
= 3) were analyzed histologically. In all six mice the tumor
nodules showed the same differentiation degree as the original
tumor. These apparently growing nodules were surrounded by
areas of necrotic tumor and fibrosis. CEA expression in the
numerous pseudolumina of the relapsing nodules was deter-
mined by immunocytochemistry and was as abundant as in
the untreated tumors.
Histology of remaining micronodules in mice with com-
plete remission. The small nodules remaining at the site of
tumor transplantation in five successfully treated mice of ex-
periment 1 (Fig. 1) 6 mo after therapy contained mostly fi-
brosis, and in three cases some rare cells of epithelial origin
(encapsulated in fibrosis) with no sign of cell division. Among
the 10 mice of experiment 3 (Fig. 3) who had all complete
tumor remission, 2 mice were sacrificed 4 and 8 mo after
therapy, and the 8 others (in good health) at 12 mo. No evi-
dence oftumor relapse was found at autopsy. Histologic exam-
ination of the small (tumor) nodules showed fibrosis with no
tumor cells in nine mice and some remaining epithelial cells
(without sign of cell division) surrounded by fibrosis in the
mouse that was killed at 4 mo.
Discussion
Several reports from the literature describe delayed tumor
growth (27-30) and in some cases complete remission of solid
tumors in nude mice by treatment with various MAbs (31-39).
Complete remissions, however, were often obtained by initiat-
ing antibody treatment within 24 h after tumor transplanta-
tion, when the tumor cells are not yet established and orga-
nized (31-33, 35, 37). Thus, these tumor remissions should
rather be considered as prevention of engraftment. In other
experiments very large doses of radioactivity on intact anti-
bodies were injected, which caused severe radiation toxicity
and death of a high percentage of the treated animals (36,
38, 39).
In the present experiments we started therapy 9-10 d after
tumor transplantation when the human colon carcinoma xe-
nografts were well established and in exponential growth. After
injection of high doses of '31I-anti-CEA MAb F(ab')2 we could
observe complete tumor regression and long-term survival of
almost all animals. For instance, in the last group of 10 mice
injected with 2,200 ACi 311-MAb F(ab)2, only 1 animal
needed bone marrow transplantation, and 8 animals were ob-
served during 12 mo in good health without tumor relapse.
The good tolerance of high doses of radioactivity appeared
to be due to the exclusive use ofradiolabeled F(ab')2 fragments.
In a previous study, by using a '3'I-labeled mixture of intact
MAbs and F(ab')2 fragments of the same pool of three anti-
CEA MAbs, we obtained either relatively short tumor regres-
sions (25) or, when increasing the doses of '3'I, we observed, in
addition to bone marrow toxicity controlled by bone marrow
transplantation, severe liver toxicity at days 55-100 after in-
jection (unpublished data).
Surprisingly, despite the demonstration of the superiority
of fragments for diagnostic immunoscintigraphy both experi-
mentally (7, 19, 50-55) and in clinical trials (17, 19, 24), no
thorough experimental radioimmunotherapy study using ra-
diolabeled fragments has yet been reported. The only thera-
peutic use of radiolabeled antibody fragments was reported by
Larson et al. (17), who used 'III-Fab fragments for the treat-
ment of melanoma patients. Large repeated doses of '31I-Fab
were well tolerated by the patients, but the radiation doses to
the tumors were often too low, due to the rapid elimination of
the low mol wt (50 kD) Fab fragment. Fab fragments of high
affinity MAb appear to be the best carrier of isotopes for diag-
nostic immunoscintigraphy, especially when labeled with an
isotope of relatively short physical tI/2 such as 1231 (24). Their
too rapid elimination through the kidneys, however, limits
their use for therapeutic purposes, while '3II-F(ab')2 fragments
with their intermediate mol wt (100 kD) are shown here to be
able specifically to eliminate human colon carcinoma xeno-
grafts.
In addition, in preliminary experiments five mice with
larger T380 tumors measuring 350-1,500 mm3 were treated
with 2,700-3,300 uCi of 131I-MAb F(ab')2 (adapted to the
tumor volume), and the tumor sizes progressively decreased
and remained stable with volumes ranging from 35 to 300
mm3. All five mice were in good health 6 mo after therapy
(results not shown).
The dosimetric calculations for the treatment reported in
Fig. 3 indicate that in this nude mouse model an intravenous
injection of 2,200 MCi of 13'I-labeled anti-CEA MAb F(ab')2
could deliver 8,335 rad to the subcutaneous tumors with only
617 rad absorbed by the liver. This tumor to liver radiation
ratio of 13.5 is very encouraging, and our more recent results,
presented in Table I, indicate that tumor to normal tissue
radiation ratios could be further increased for all organs by
injections of lower amounts of F(ab')2 fragments.
The results obtained with 1,600 ,uCi injected in fraction-
ated doses (4 X 400 ,Ci, four complete remissions out of nine
animals) as compared with the mice injected with a single dose
of 1,600 ,uCi (one complete remission out of five animals)
indicate a slight advantage in favor of the fractionated doses.
This advantage is not statistically significant (P < 0.4), but we
interpret the results to mean that repeated injections of small
doses are at least as effective as the injection of a single high
dose.
The complete remission of colon carcinoma xenografts in
100% of the animals required the injection of high doses of
'31I-F(ab')2 (2,200 uCi). The requirement of such high doses is
essentially due to the very short initial whole body t1/2 of
F(ab')2 (- 12 h) in the mouse and as a consequence also the
relatively short t1/2 (- 24 h) in the tumor (Fig. 4). In patients,
however, the whole body and the tumor t1/2 of F(ab')2 can be
definitively longer, ranging from 24 to 48 h depending on the
amount of fragments injected (unpublished observation).
Thus, the amount ofinjected "3 I-F(ab')2 fragments required to
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sterilize a tumor in the mouse cannot be directly extrapolated
to the patients' situation.
In patients, however, we may encounter several additional
problems. First, the bone marrow tolerance to radiation is
lower in humans than in mice and the longer whole body t1/2 of
F(ab')2 in patients may lead to more bone marrow toxicity.
Second, the fact that CEA is present in normal tissues (such as
normal gut) (56) may increase binding of antibody, and con-
sequently radiation to these organs. Furthermore, the presence
ofCEA in circulation may provoke the formation ofimmune
complexes that might accumulate in the reticulo-endothelium.
In our limited clinical experience in the treatment of liver
metastases from colon carcinoma by injection of large doses of
'3'I (100-300 mCi) linked to anti-CEA MAb (intact and
F(ab')2 fragments) we have not yet obtained significant tumor
remission (Delaloye et al., manuscript in preparation, and ref-
erence 26). The only limitation, however, has been bone mar-
row toxicity, a problem that might be overcome by using au-
tologous bone marrow transplantation.
Without underestimating the obvious differences between
clinical and experimental radioimmunotherapy, we consid-
ered it important in the present study to select experimental
conditions as close as possible to the clinical situation, includ-
ing a systemic route of antibody administration, the treatment
of well-established human carcinoma xenografts, and the use
of F(ab')2 fragments from anti-CEA MAbs which had been
shown to be well tolerated in patients (26).
We have demonstrated that complete ablation of human
colon carcinoma xenografts in nude mice can be obtained by a
single or by repeated intravenous injections of '31I-anti-CEA
MAb F(ab')2. Interestingly, the different treatments described
here were well tolerated by the animals, since out of 19 mice
with complete tumor remission, only 4 required bone marrow
transplantation and 17 were in good health with no detectable
tumor after a follow-up of 6-12 mo. The results obtained in
this well-controlled experimental model may be useful as ref-
erence for the planning of radioimmunotherapy in colorectal
carcinoma patients.
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